Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Gains from Investment Securities (2019)

Historic Gains from Investment Securities for RedHill Biopharma (RDHL) over the last 4 years, with Q4 2022 value amounting to $823000.0.

  • RedHill Biopharma's Gains from Investment Securities rose 110365.85% to $823000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $5.6 million, marking a year-over-year increase of 44377.43%. This contributed to the annual value of $270000.0 for FY2023, which is 9516.99% down from last year.
  • RedHill Biopharma's Gains from Investment Securities amounted to $823000.0 in Q4 2022, which was up 110365.85% from $4.8 million recorded in Q1 2022.
  • In the past 5 years, RedHill Biopharma's Gains from Investment Securities ranged from a high of $4.8 million in Q1 2022 and a low of -$82000.0 during Q4 2021
  • Its 4-year average for Gains from Investment Securities is $1.1 million, with a median of $630000.0 in 2020.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 14270.83% in 2021, then soared by 110365.85% in 2022.
  • Over the past 4 years, RedHill Biopharma's Gains from Investment Securities (Quarter) stood at $124000.0 in 2019, then surged by 54.84% to $192000.0 in 2020, then tumbled by 142.71% to -$82000.0 in 2021, then skyrocketed by 1103.66% to $823000.0 in 2022.
  • Its Gains from Investment Securities was $823000.0 in Q4 2022, compared to $4.8 million in Q1 2022 and -$82000.0 in Q4 2021.